Clinical TrialsNkarta is preparing for preliminary data from Ntrust-1 and Ntrust-2 clinical trials, which will provide the first look at the efficacy of NKX019 for treating various autoimmune diseases.
Competitive AdvantageCAR-NK cell therapies may have a number of advantages over autologous CAR-T cell therapies including safety differentiation with lack of CRS and neurotoxicity.
Financial StabilityNkarta had cash, cash equivalents, and restricted cash of $334.0 million, which should be sufficient to fund operations into 2029.